SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus shares are drawing attention amid a steep, volatile selloff, with traders blaming share dilution from equity and warrant offerings, a rich valuation, and the cost and execution risks of expanding enrichment capacity. Bulls counter that DOE and commercial fuel contracts support the longer-term domestic nuclear-fuel and HALEU opportunity, while bearish traders question when that growth will translate into results.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs ahead of the Q3 report has traders focused on BRIUMVIs sales momentum and the possibility of stronger guidance. The community also points to heavy call activity and short interest, while debating whether the rally reflects earnings positioning and momentum or unconfirmed buyout speculation; upcoming subcutaneous BRIUMVI data is another catalyst in view.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of a competing treatment for recurrent respiratory papillomatosis has raised concerns about competition for Precigens PAPZIMEOS and prompted debate over its potential effect on sales. Traders weigh the rivals dosing advantages against PAPZIMEOS commercial head start, established payer access and stronger first-year response data, while also watching Precigens upcoming earnings for evidence of continued uptake.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs large equity raise and stock-funded Elisity acquisition have put dilution and capital allocation at the center of discussion as shares sell off. Some traders see the deal as extending the company into cybersecurity and broader quantum infrastructure, while others question its value per share and want evidence that acquisitions and quantum programs can translate into recurring revenue.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios post-earnings selloff follows a Q3 beat and higher full-year outlook, as its Q4 organic growth guidance signaled a slowdown from the prior quarter. Traders are divided between viewing the drop as an overreaction with bounce potential and waiting for the stock to stabilize as investors reassess the growth outlook.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbases selloff is being tied to Q3 results that beat on headline EPS but showed weaker trading revenue and operating performance, with much of reported profit attributed to gains on crypto holdings; the Binance hack and broader crypto-market weakness have added pressure. Traders disagree on whether the breach could send users to Coinbase or deepen concerns about exchange security and crypto demand.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarnas steep post-earnings slide and persistent weak trading dominate the discussion, with traders debating whether concerns about guidance, profitability and ongoing selling pressure explain the decline or whether the stock is oversold ahead of Q3 results. Bulls cite Apple and payments partnerships and longer-term BNPL growth, while frustrated holders question why the shares keep lagging.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

The European Lithium acquisition and resulting CRML share issuance are driving debate, with some traders concerned about dilution and potential selling pressure while others see the added cash and assets, including greater ownership of Tanbreez, as a positive. High-borrow-cost and short-squeeze speculation is also prominent, though traders disagree on whether it will lead to sustained buying.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 78,059.66839082 USD and is up 0.67 over the last 24 hours. It is currently trading on 12773 active market(s) with $13,095,082,899.62 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

The massive Binance hack and the exchanges resumption of withdrawals have put crypto security, customer outflows, and potential market contagion at the center of Bitcoin discussion. Traders are divided: bears warn of further selling and exchange-liquidity risks, while bulls argue Bitcoins resilience through the incident supports a recovery.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,023,844,090.614844 with 95,023,861,343.880544 in circulation. The last known price of TRON is 0.3125405 USD and is up 1.67 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,085,916,839.31 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRONs steady price action and relative resilience versus other cryptocurrencies are drawing attention, with traders debating whether consolidation signals another breakout or a corrective pullback. Some also point to the networks role in stablecoin transfers as support for the longer-term bullish case, while others remain frustrated by its subdued moves.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)PR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12...

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte

Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.

CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’

Equity

H.C. Wainwright called the Phase 3 results a “compelling” late-stage assessment of Barzolvolimab in a patient population with a significant unmet need.

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) PR Newswire NEW YORK, Aug. 24, 2026 NEW YORK, Aug...

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging  Celldex Therapeutics (CLDX) This Year?

Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.

CLDX Stock Down 10% After-Hours — What’s Driving The Selloff?

Celldex announced that its experimental drug barzolvolimab missed key goals in a mid-stage study for prurigo nodularis. 

Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?

Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval...

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Celldex Therapeutics Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>The brokerage raised the price target on Celldex to $64 from $42 and maintained a ‘Buy’ rating, according to The Fly.</li><li>Celldex’s Phase 3 studies met their primary and all key secondary endpoints for Barzolvolimab in chronic spontaneous urticaria.</li><li>The biotech firm plans to submit a BLA to the FDA in 2027.</li></ul>Celldex Therapeutics (CLDX) received a major price target hike on Tuesday, despite the stock crashing nearly 20%, after its experimental treatment for a skin condition delivered positive results in two late-stage studies.H.C. Wainwright raised the price target on Celldex to $64 from $42 and maintained a ‘Buy’ rating, according to The Fly. The updated target implies a nearly 90% upside from current levels.<h2 class="st-heading-2">Barzolvolimab Meets All Key Goals</h2>Celldex said both Phase 3 Embarq-CSU1 and Embarq-CSU2 studies of Barzolvolimab met their primary and all key secondary endpoints at 12 weeks. The drug is being developed for the treatment of chronic spontaneous urticaria (CSU), a skin condition that causes recurring hives and swelling.At Week 12, about 42% to 46% of patients receiving Barzolvolimab achieved a complete response, meaning they experienced no hives or itching, compared with roughly 9% to 13% of patients receiving placebo.Results strengthened further by Week 24, with complete response rates reaching 54%. The studies enrolled 1,939 patients.Celldex plans to file the Biologics License Application (BLA) with the FDA in 2027.Despite the results, <a href="https://stocktwits.com/symbol/CLDX">CLDX shares</a> initially plunged nearly 20% before trimming losses. At the time of writing, the stock traded around 11% lower.<h2 class="st-heading-2">Why Did CLDX Stock Slump Despite Positive Data?</h2>Despite the strong efficacy results, investors focused on the study’s safety data. Two cases were classified as probable Grade 4 anaphylaxis, a severe and potentially life-threatening allergic reaction to the drug. Celldex noted that one occurred after a placebo dose.H.C. Wainwright said the stock fell due to “misplaced focus/correction to announced safety metrics,” arguing that the Phase 3 results provide a “compelling, well-powered, controlled late-stage assessment” of Barzolvolimab in a patient population with significant unmet need.<h2 class="st-heading-2">Retail Split On Safety Data</h2>Despite the stock tanking, retail sentiment surrounding CLDX on Stocktwits flipped to ‘extremely bullish’ from ‘neutral’ over the past 24 hours, amid ‘extremely high’ message volumes.One user called the selloff an “overreaction.”<stembedurl>https://stocktwits.com/JayelesVentures/message/664788729</stembedurl>However, another user believes it’s a “classic sell the news event.”<stembedurl>https://stocktwits.com/TA_Kongen/message/664787362</stembedurl>The stock has gained more than 24% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/msft-layoffs-microsoft-cuts-xbox-jobs/cZMPtYuRBeC">MSFT Layoffs: Microsoft Cuts 268 Xbox Jobs As Gaming Reset Deepens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Celldex Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$CLDX Celldex Therapeutics shares are under heavy pressure as traders focus on fresh safety worries tied to its lead drug, barzolvolimab. While the Phase 3 trial in chronic spontaneous urticaria hit its main goals, reports of two life-threatening anaphylaxis cases, a long regulatory path stretching into 2027, and a classic “sell the news” reaction have combined to overshadow the efficacy win and weigh on the stock. The setback comes even as the strong Phase 3 data reinforce the drug’s potential and underscore the value of Celldex’s antibody-focused pipeline, which could support the company’s long-term prospects if it successfully navigates regulators and competition.

puppis

$CLDX  Oct. calls expired worthless. 1 month til the Nov. ones do too. Then might see some upward momentum

Steve

$CLDX Celldex Therapeutics: FMR reports 10.7% stake 
FMR LLC reports sole voting power over 8,396,651 shares, while reporting person Abigail P. Johnson reports none.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CLDX Celldex Therapeutics Inc.

Fundamentals

Latest CLDX News